{"id":767715,"date":"2023-07-05T09:00:10","date_gmt":"2023-07-05T13:00:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\/"},"modified":"2023-07-05T09:00:10","modified_gmt":"2023-07-05T13:00:10","slug":"biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\/","title":{"rendered":"Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets"},"content":{"rendered":"
\n

SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc<\/a>. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has completed an agreement with a large diagnostics company for the sale of legacy assets related to Biora\u2019s former diagnostics business.<\/p>\n

\u201cThis represents continued progress in monetizing our legacy assets,\u201d said Eric d\u2019Esparbes, Chief Financial Officer of Biora Therapeutics. \u201cThis transaction provides incremental non-dilutive funding to advance our therapeutics platforms, while enabling the assets to be leveraged for important diagnostic applications.\u201d<\/p>\n

Biora Therapeutics will receive a one-time payment for the sale of assets including rights to certain antibody sequences. Specific terms of the agreement were not disclosed.<\/p>\n

\n About Biora Therapeutics<\/strong>
\n
Biora Therapeutics is the biotech company that is reimagining therapeutic delivery. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients\u2019 lives.<\/p>\n

Biora is focused on development of two therapeutics platforms: the NaviCap\u2122 targeted oral delivery platform<\/a>, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract, and the BioJet\u2122 systemic oral delivery platform<\/a>, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules.<\/p>\n

For more information, visit bioratherapeutics.com<\/a> or follow the company on LinkedIn<\/a> or Twitter<\/a>.<\/p>\n

\n Safe Harbor Statement or Forward-Looking Statements<\/strong>
\n
This press release contains \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development and clinical efforts, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cobjective,\u201d \u201cintend,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201ccan,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201cdesign,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cplan,\u201d \u201ctarget,\u201d or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future filings and initiate clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators, our ability to raise sufficient capital to achieve our business objectives, the ongoing COVID-19 pandemic, and those risks described in \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC and other subsequent documents, including Quarterly Reports, that we file with the SEC.<\/p>\n

Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n

\n Investor Contact<\/strong>
\n
Chuck Padala
Managing Director, LifeSci Advisors
IR@bioratherapeutics.com<\/a>
(646) 627-8390<\/p>\n

\n Media Contact<\/strong>
\n
\n media@bioratherapeutics.com<\/a>\n <\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has completed an agreement with a large diagnostics company for the sale of legacy assets related to Biora\u2019s former diagnostics business. \u201cThis represents continued progress in monetizing our legacy assets,\u201d said Eric d\u2019Esparbes, Chief Financial Officer of Biora Therapeutics. \u201cThis transaction provides incremental non-dilutive funding to advance our therapeutics platforms, while enabling the assets to be leveraged for important diagnostic applications.\u201d Biora Therapeutics will receive a one-time payment for the sale of assets including rights to certain antibody sequences. Specific terms of the agreement were not disclosed. About Biora Therapeutics Biora Therapeutics is the biotech … <\/p>\n

Continue reading “Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-767715","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBiora Therapeutics Continues to Monetize Legacy Diagnostics Assets - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has completed an agreement with a large diagnostics company for the sale of legacy assets related to Biora\u2019s former diagnostics business. \u201cThis represents continued progress in monetizing our legacy assets,\u201d said Eric d\u2019Esparbes, Chief Financial Officer of Biora Therapeutics. \u201cThis transaction provides incremental non-dilutive funding to advance our therapeutics platforms, while enabling the assets to be leveraged for important diagnostic applications.\u201d Biora Therapeutics will receive a one-time payment for the sale of assets including rights to certain antibody sequences. Specific terms of the agreement were not disclosed. About Biora Therapeutics Biora Therapeutics is the biotech … Continue reading "Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-05T13:00:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2Nzk3MSM1Njc0MTQzIzIxOTQ1MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets\",\"datePublished\":\"2023-07-05T13:00:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\\\/\"},\"wordCount\":614,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2Nzk3MSM1Njc0MTQzIzIxOTQ1MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\\\/\",\"name\":\"Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2Nzk3MSM1Njc0MTQzIzIxOTQ1MTc=\",\"datePublished\":\"2023-07-05T13:00:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2Nzk3MSM1Njc0MTQzIzIxOTQ1MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2Nzk3MSM1Njc0MTQzIzIxOTQ1MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\/","og_locale":"en_US","og_type":"article","og_title":"Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets - Market Newsdesk","og_description":"SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has completed an agreement with a large diagnostics company for the sale of legacy assets related to Biora\u2019s former diagnostics business. \u201cThis represents continued progress in monetizing our legacy assets,\u201d said Eric d\u2019Esparbes, Chief Financial Officer of Biora Therapeutics. \u201cThis transaction provides incremental non-dilutive funding to advance our therapeutics platforms, while enabling the assets to be leveraged for important diagnostic applications.\u201d Biora Therapeutics will receive a one-time payment for the sale of assets including rights to certain antibody sequences. Specific terms of the agreement were not disclosed. About Biora Therapeutics Biora Therapeutics is the biotech … Continue reading \"Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-05T13:00:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2Nzk3MSM1Njc0MTQzIzIxOTQ1MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets","datePublished":"2023-07-05T13:00:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\/"},"wordCount":614,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2Nzk3MSM1Njc0MTQzIzIxOTQ1MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\/","name":"Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2Nzk3MSM1Njc0MTQzIzIxOTQ1MTc=","datePublished":"2023-07-05T13:00:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2Nzk3MSM1Njc0MTQzIzIxOTQ1MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2Nzk3MSM1Njc0MTQzIzIxOTQ1MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-continues-to-monetize-legacy-diagnostics-assets\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/767715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=767715"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/767715\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=767715"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=767715"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=767715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}